代谢组学与整合网络药理学揭示活心丸抗心肌肥厚机制
该研究用异丙肾上腺素诱导60只大鼠心肌肥厚模型,观察活心丸的作用。结果显示活心丸可减轻肥厚指数与病理损伤、降低氧化应激,网络药理学提示PI3K-Akt通路为主要机制,实验验证其通过激活该通路抑制心肌细胞凋亡;代谢组学鉴定21个差异代谢物。
要点
- 活心丸可减轻异丙肾上腺素诱导的大鼠心肌肥厚与病理损伤。
- 活心丸通过激活PI3K-Akt通路抑制心肌细胞凋亡。
- 代谢组学发现21个差异代谢物,其中6个上调、15个下调。
核心结论
- 活心丸通过激活PI3K-Akt通路抑制心肌细胞凋亡,并调节代谢标志物,从而减轻心肌肥厚。
研究设计与样本
- 研究纳入60只大鼠,采用异丙肾上腺素注射建立心肌肥厚模型。
- 通过超声心动图与组织病理学评估病情,ELISA检测氧化应激,网络药理学与代谢组学分析关键成分、靶点与通路,Western blotting与免疫组化检测凋亡蛋白。
主要发现
- 与仅注射异丙肾上腺素的大鼠相比,活心丸给药组肥厚指数降低、心脏病理损伤减轻、氧化应激水平下调。
- 网络药理学提示PI3K-Akt通路是活心丸抑制心肌肥厚的主要机制,实验验证活心丸通过激活PI3K-Akt通路抑制心肌细胞凋亡。
- 代谢组学分析鉴定出活心丸高剂量组与异丙肾上腺素组之间21个差异代谢物,其中6个显著上调、15个显著下调,被视为活心丸治疗心肌肥厚的代谢生物标志物。
临床怎么用
- 为活心丸用于心肌肥厚(冠心病重要阶段)提供实验机制依据,支持其通过PI3K-Akt通路及代谢调节发挥心脏保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Cardiac hypertrophy (CH) is maladaptive and contributes to the pathogenesis of heart failure. Huoxin pill (HXP), a Chinese herbal prescription, is widely applied in the treatment of cardiovascular disease (CAD). Its mechanism, however, is unclear. AIM OF THE STUDY: This study investigated the mechanism of action for Huoxin pill in the treatment of CH, an important stage of CAD. MATERIALS AND METHODS: A total of 60 rats were injected with isoprenaline (ISO) to establish a model of CH. Echocardiography and histopathologic evaluation were performed to evaluate the disease severity, whereas ELISAs were conducted to determine the expression of oxidative stress. Network pharmacology and metabolomic analyses were conducted to identify the key compounds, core targets and pathways that mediate the effects of HXP against CH. Western blotting and immunohistochemistry were used to test apoptosis protein levels. RESULTS: HXP administration in ISO-treated rats decreased hypertrophy indices, alleviated cardiac pathological damage, and downregulated oxidative stress levels when compared to those of rats subjected to ISO treatment only. Moreover, network pharmacology results suggested that the PI3K-Akt pathway is a main mechanism by which HXP inhibits cardiac hypertrophy, and experimental verification showed that HXP inhibited cardiomyocyte apoptosis via activation of the PI3K-Akt pathway. The results of metabolomic analysis identified 21 differential metabolites between the HXPH group and ISO group, which were considered to be metabolic biomarkers of HXP in the treatment of CH. Among them, 6 differential metabolites were significantly upregulated, and 15 were significantly downregulated. CONCLUSIONS: The present study presents an integrated strategy for investigating the mechanisms of HXP in the treatment of CH and sheds new light on the application of HXP as a traditional Chinese medicine.
引用
- Gao ZW, Zhang X, Zhuo QY, et al. Metabolomics and integrated network pharmacology analysis reveal attenuates cardiac hypertrophic mechanisms of HuoXin pill. J Ethnopharmacol. 2022. PMID: 35304274. doi:10.1016/j.jep.2022.115150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。